The prognosis of MM patients is affected by many factors, such as international staging system, cytogenetic abnormality, underlying disease and age [32], studies have shown that IFI16 can be used as a biomarker for poor prognosis in MM [33]. The gene discussed is IFI16; the disease is Miyoshi myopathy.